See more : Northern Minerals Limited (NTU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of PD-Rx Pharmaceuticals, Inc. (PDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PD-Rx Pharmaceuticals, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Income Statement Analysis – Financial Results
- Kontigo Care AB (publ) (KONT.ST) Income Statement Analysis – Financial Results
- JB Hi-Fi Limited (JBHIF) Income Statement Analysis – Financial Results
- Samyang Tongsang Co., Ltd (002170.KS) Income Statement Analysis – Financial Results
- CBLT Inc. (CBBLF) Income Statement Analysis – Financial Results
PD-Rx Pharmaceuticals, Inc. (PDRX)
About PD-Rx Pharmaceuticals, Inc.
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company provides approximately 2,600 prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, suspensions, etc. It also offers PD-Rx Net, a web-based application that tracks prescriptions filled at the point of care and print prescription labels for prescription that filled onsite; and manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a convenient handling package for physician dispensing customers. In addition, the company provides professional assistance by staffed pharmacists and physicians; and pharmaceutical sampling program design to reduce MCO's pharmaceutical costs, as well as allows medical professionals to offer pre-filled prescriptions to patients free of charge. It serves physicians, pharmacies, and medical clinics. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is headquartered in Oklahoma City, Oklahoma.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.27M | 28.72M | 21.60M | 21.03M | 20.87M | 24.97M | 25.99M | 21.47M | 19.39M | 29.12M | 26.02M |
| Cost of Revenue | 14.56M | 17.65M | 14.65M | 14.77M | 13.29M | 16.43M | 18.15M | 13.90M | 11.71M | 18.94M | 17.81M |
| Gross Profit | 6.71M | 11.06M | 6.96M | 6.26M | 7.58M | 8.54M | 7.84M | 7.57M | 7.67M | 10.18M | 8.21M |
| Gross Profit Ratio | 31.56% | 38.52% | 32.20% | 29.77% | 36.34% | 34.19% | 30.16% | 35.25% | 39.58% | 34.96% | 31.56% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.73M | 6.97K | 6.08M | 0.00 | 7.65M | 7.48M | 6.72M | 0.00 | 0.00 | 6.84M | 6.07M |
| Selling & Marketing | 171.00K | 92.00K | 88.00K | 0.00 | 158.00K | 162.00K | 143.00K | 0.00 | 0.00 | 247.00K | 201.00K |
| SG&A | 6.90M | 7.06M | 6.08M | 6.50M | 7.65M | 7.64M | 6.86M | 6.80M | 6.79M | 7.09M | 6.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.90M | 7.03M | 6.08M | 6.50M | 7.65M | 7.64M | 6.86M | 6.80M | 6.79M | 7.09M | 6.27M |
| Cost & Expenses | 21.46M | 24.68M | 20.73M | 21.26M | 20.94M | 24.08M | 25.01M | 20.70M | 18.51M | 26.03M | 24.08M |
| Interest Income | 61.70K | 17.45 | 0.00 | 0.00 | 0.00 | 71.98K | 54.31K | 36.03K | 43.80K | 33.05K | 25.81K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 139.06K | 126.88K | 114.63K | 161.03K | 177.33K | 176.54K | 153.97K | 172.00K | 190.19K | 187.19K | 180.79K |
| EBITDA | -51.42K | 4.13M | 1.95M | -39.51K | 162.89K | 1.16M | 1.18M | 970.30K | 1.07M | 3.31M | 2.12M |
| EBITDA Ratio | -0.24% | 14.39% | 4.59% | -0.36% | 0.53% | 4.27% | 4.34% | 4.36% | 5.52% | 11.26% | 8.15% |
| Operating Income | -190.48K | 4.00M | 876.47K | -237.65K | -65.73K | 890.72K | 973.84K | 763.17K | 880.71K | 3.09M | 1.94M |
| Operating Income Ratio | -0.90% | 13.95% | 4.06% | -1.13% | -0.31% | 3.57% | 3.75% | 3.55% | 4.54% | 10.61% | 7.45% |
| Total Other Income/Expenses | 63.70K | 48.38K | 958.22K | 37.12K | 51.30K | 90.08K | 56.61K | 35.13K | 43.80K | 33.05K | 25.81K |
| Income Before Tax | -126.78K | 4.05M | 1.83M | -200.53K | -14.44K | 980.80K | 1.03M | 798.30K | 924.51K | 3.12M | 1.97M |
| Income Before Tax Ratio | -0.60% | 14.11% | 8.49% | -0.95% | -0.07% | 3.93% | 3.97% | 3.72% | 4.77% | 10.73% | 7.55% |
| Income Tax Expense | 28.71K | 1.02M | -21.63K | 183.61K | -1.52K | 359.64K | 403.49K | 290.63K | 383.96K | 1.16M | 734.37K |
| Net Income | -98.06K | 3.03M | 1.86M | -384.14K | -12.92K | 621.16K | 626.97K | 507.67K | 540.55K | 1.96M | 1.23M |
| Net Income Ratio | -0.46% | 10.57% | 8.59% | -1.83% | -0.06% | 2.49% | 2.41% | 2.36% | 2.79% | 6.74% | 4.73% |
| EPS | -0.06 | 1.83 | 1.08 | -0.22 | -0.01 | 0.36 | 0.36 | 0.30 | 0.31 | 1.13 | 0.70 |
| EPS Diluted | -0.06 | 1.83 | 1.08 | -0.22 | -0.01 | 0.36 | 0.36 | 0.30 | 0.31 | 1.13 | 0.70 |
| Weighted Avg Shares Out | 1.63M | 1.66M | 1.72M | 1.72M | 1.72M | 1.72M | 1.72M | 1.72M | 1.74M | 1.74M | 1.76M |
| Weighted Avg Shares Out (Dil) | 1.63M | 1.66M | 1.72M | 1.72M | 1.72M | 1.72M | 1.72M | 1.72M | 1.74M | 1.74M | 1.76M |
Source: https://incomestatements.info
Category: Stock Reports